The Medical Letter on Drugs and Therapeutics: Difference between revisions
Mabramowicz (talk | contribs) |
Mabramowicz (talk | contribs) No edit summary |
||
Line 11:
}}
'''''The Medical Letter on Drugs and Therapeutics''''', commonly referred to as ''The Medical Letter'',
The Medical Letter has a print and electronic circulation of
Published biweekly (26 issues/year), the newsletter is available in several languages: [[English language|English]] (US and Canadian editions), [[French language|French]] (Canadian and European editions), [[Italian language|Italian]], [[Japanese language|Japanese]], and [[Spanish language|Spanish]].The Medical Letter is also available as an electronic site license for institutions such as medical schools, hospitals and group practices.
|
Revision as of 22:33, 25 April 2011
Discipline | Publication |
---|---|
Language | English, French, Italian, Japanese, Spanish and a Canadian adapted version, written in English |
Publication details | |
History | first published 1959 |
Publisher | |
Standard abbreviations | |
ISO 4 | Med Lett Drugs Ther |
Indexing | |
ISSN | 1523-2859 |
Links | |
The Medical Letter on Drugs and Therapeutics, commonly referred to as The Medical Letter, publishes independent evaluations of therapeutic drugs on the basis of novel information. It has been considered the gold standard for new drug review within the medical community for over five decades.
The Medical Letter has a print and electronic circulation of more than 450,000 subscribers in 125 countries worldwide.
Published biweekly (26 issues/year), the newsletter is available in several languages: English (US and Canadian editions), French (Canadian and European editions), Italian, Japanese, and Spanish.The Medical Letter is also available as an electronic site license for institutions such as medical schools, hospitals and group practices.
The Medical Letter is published by The Medical Letter, Inc., which also publishes the monthly Treatment Guidelines from The Medical Letter.
Editorial process
Articles for The Medical Letter are drafted by either an in-house editor or outside expert using both published and available unpublished studies that are reviewed for methodological rigor with special attention to the results of clinical trials. A preliminary draft is circulated to the publication's contributing editors and to 10-20 other reviewers with relevant clinical or experimental experience with the topic. Drafts are also provided to the Food and Drug Administration (FDA) and to the first authors of all the articles cited in the text. The evaluation of each drug includes a discussion of its efficacy, side effects, and a comparison with older, more established agents. The final version of the article, which includes comments from the reviewers, is checked and edited to make sure it is both accurate and readable.[1]
See also
References
- ^ "Flowchart of the editorial process" (pdf). The Medical Letter, Inc. Retrieved 2010-06-29.